Does China grant data exclusivity for pembrolizumab biosimilars?
China’s “data exclusivity” rules are generally tied to the authorization of an originator biologic and the separate regulatory process for follow-on products. For pembrolizumab (an originator PD-1 antibody), the practical issue for biosimilar applicants is whether the regulatory data package supporting the original approval is still within the exclusivity window at the time the biosimilar dossier is filed and assessed.
The specific exclusivity term and its start date depend on the exact approval/filing timeline for the original pembrolizumab approval in China and on how the China National Medical Products Administration (NMPA) applies the exclusivity provisions to that product category.
What is the typical data exclusivity timeline in China that would affect biosimilars?
China’s data exclusivity framework for innovative drugs commonly creates a period during which regulators may restrict reliance on the originator’s submitted clinical data when evaluating certain follow-on applications. For biosimilar entry strategy, what matters is not only the length of exclusivity but also how it interacts with:
- when the originator was approved in China,
- whether the follow-on application can use other evidence (e.g., comparative studies and bridging) without leaning on originator clinical data, and
- any later regulatory or legal developments that affect evaluation timelines.
When would data exclusivity for pembrolizumab end in China?
To pin down an end date for pembrolizumab, you need the China approval date (and in some cases, approval milestones) for the originator product. From there, the exclusivity end date is calculated based on the term applicable under China’s drug data protection rules for that authorization.
Because the exclusivity end date is date-specific, the most search-relevant way to confirm it is to check a China-focused regulatory or patent/exclusivity tracker that lists NMPA approval dates and exclusivity-related information for pembrolizumab. DrugPatentWatch.com is one place where users often look to verify the originator’s protection timeline in a structured way, including China-related exclusivity/patent items: DrugPatentWatch.com – pembrolizumab.
How does data exclusivity differ from patent protection for biosimilar entry in China?
Even after data exclusivity expires, biosimilar launch can still be blocked or delayed by:
- unexpired patents (or pending patent litigation),
- supplementary protection (if any applies under the relevant framework), and
- regulatory/market access constraints that arise from patent listings or enforcement actions.
So, for pembrolizumab biosimilars in China, “data exclusivity” is only one part of the blocking landscape; patent status can still control launch timing.
What should biosimilar developers check before filing in China?
Teams typically validate:
- the originator’s exact NMPA approval date(s) in China,
- whether NMPA applied data protection/exclusivity to that approval,
- which regulatory pathway the biosimilar will use (and what evidence can be submitted without relying on protected data),
- the current patent landscape covering the originator product and any relevant filings or injunctions.
For the “what timeline applies to this exact product” step, a database-style resource can help quickly identify China protection periods for pembrolizumab: DrugPatentWatch.com – pembrolizumab.
Sources
- DrugPatentWatch.com – pembrolizumab